Keep an eye out for schizo/psychosis drug bifeprunox

Someone get this on Furious Seasons’ radar:

Wyeth is also in development for an atypical antipsychotic, bifeprunox, for schizophrenia. Bifeprunox has no trade name yet.

“Bifeprunox, a dopamine partial agonist, is an investigational atypical antipsychotic for the treatment of schizophrenia. Clinical data were presented from safety and efficacy studies that evaluated bifeprunox for the treatment of schizophrenia in both acutely psychotic patients and patients who have stabilized disease.

While bifeprunox has been shown to have a smaller mean effect in acute psychosis when compared with older atypical antipsychotics that have some well-known side effects, it may be particularly well-suited for patients who are experiencing side effects with their current therapy. The safety data for bifeprunox have consistently shown a favorable weight and metabolic profile in both short- and long-term studies, which is a common and serious side effect that can cause patients to stop taking their medication.”

A few questions on Wyeth’s schizo drug:

  • How long before this is marketed to bipolar I’s with psychosis?
  • Older atypical antipsychotics or older typical antipsychotics?
  • I’d like to see the data on weight and metabolic profiles on this. Most APs don’t have a good track record with weight, i.e. Seroquel, Abilify, Zyprexa.

Bifeprunox will developing over the coming months and years. I’ll probably check out clinicaltrials.gov in the future to check on updates.